XML 66 R43.htm IDEA: XBRL DOCUMENT
v3.19.2

INTANGIBLE ASSETS (Details Narrative) $ / shares in Units, € in Millions |  |  | 3 Months Ended | 6 Months Ended |
--- | --- | --- | --- | --- | ---
Aug. 06, 2018 USD ($) $ / shares shares | Jul. 30, 2018 USD ($) | Jun. 30, 2019 USD ($) | Mar. 31, 2019 USD ($) | Jun. 30, 2018 USD ($) | Jun. 30, 2019 USD ($) | Jun. 30, 2018 USD ($) | Jun. 30, 2019 EUR (€) | Jun. 30, 2019 USD ($)
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |
Intangible written offf |  |  |  |  |  | $ 78,864 |  |  |
Sales milestone payments | € |  |  |  |  |  |  |  | € 27.5 |
Regulatory milestone payment due | € |  |  |  |  |  |  |  | 2.0 |
Cash upfront payment due | € |  |  |  |  |  |  |  | € 14.0 |
Amortization expense |  |  | $ 48,503 |  | $ 24,826 | $ 88,948 | $ 46,023 |  |
Approved Hormone Therapy Drug Candidate Patents [Member] |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |
Useful Life |  |  |  |  |  | 20 years |  |  |
Domestic U.S. Patents [Member] |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |
Number of issued patents |  |  |  |  |  |  |  | 26 | 26
Foreign Patents [Member] |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |
Number of issued patents |  |  |  |  |  |  |  | 27 | 27
Domestic Utility Patents [Member] |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |
Number of issued patents |  |  |  |  |  |  |  | 12 | 12
Foreign Utility Patents [Member] |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |
Number of issued patents |  |  |  |  |  |  |  | 5 | 5
Domestic Patents - TX-004HR [Member] |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |
Number of issued patents |  |  |  |  |  |  |  | 5 | 5
Foreign Patents - TX-004HR [Member] |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |
Number of issued patents |  |  |  |  |  |  |  | 13 | 13
Domestic Utility Patent - Transdermal Patch Candidates [Member] |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |
Number of issued patents |  |  |  |  |  |  |  | 1 | 1
Foreign Utility Patent - Transdermal Patch Candidates [Member] |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |
Number of issued patents |  |  |  |  |  |  |  | 5 | 5
Domestic Utilty Patent - Opera Software [Member] |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |
Number of issued patents |  |  |  |  |  |  |  | 1 | 1
Domestic Utility Patents Topical - Cream Candidates [Member] |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |
Number of issued patents |  |  |  |  |  |  |  | 1 | 1
Domestic Patents - TX-009HR [Member] |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |
Number of issued patents |  |  |  |  |  |  |  | 2 | 2
Foreign Patents Progesterone - Only Candidate [Member] |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |
Number of issued patents |  |  |  |  |  |  |  | 4 | 4
Domestic utility patent D-limonene [Member] [Default Label] |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |
Number of issued patents |  |  |  |  |  |  |  | 1 | 1
Subscription Agreement [Member] | Knight Therapeutics Inc. [Member] |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |
Issue of common stock shares (in shares) | shares | 3,921,568 |  |  |  |  |  |  |  |
Gross proceeds | $ 20,000,000 |  |  |  |  |  |  |  |
Common stock sale price (in dollars per share) | $ / shares | $ 5.10 |  |  |  |  |  |  |  |
Minimum [Member] |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |
Annual net sales milestones | € |  |  |  |  |  |  |  | € 25.0 |
Maximum [Member] |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |
Annual net sales milestones | € |  |  |  |  |  |  |  | € 100.0 |
Council License Agreement [Member] |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |
Payment of milestone recorded as finite-lived intangible asset |  | $ 20,000,000,000 |  |  |  |  |  |  |
Council License Agreement [Member] | ANNOVERA [Member] |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |
Milestone payments upon FDA approval |  |  |  |  |  |  |  |  | $ 20,000,000
Milestone payments (payment after release of first commercial batch) |  |  |  |  |  |  |  |  | $ 20,000,000,000
Annual royalty rate reduction of initial rate during the six-month period from commercial sale of a generic equivalent |  |  |  | 50.00% |  |  |  |  |
Annual royalty rate reduction of initial rate after the six-month period from commercial sale of a generic equivalent |  |  |  | 20.00% |  |  |  |  |
Step-based Royalty Payment One [Member] | Council License Agreement [Member] | ANNOVERA [Member] |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |
Royalty (percent) |  |  |  |  |  |  |  | 5.00% | 5.00%
Step-based Royalty Payment One [Member] | Council License Agreement [Member] | ANNOVERA [Member] | Maximum [Member] |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |
Net sales amount per step-based royalty |  |  |  |  |  | $ 50,000,000 |  |  |
Step-based Royalty Payment Three [Member] | Council License Agreement [Member] | ANNOVERA [Member] |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |
Royalty (percent) |  |  |  |  |  |  |  | 15.00% | 15.00%
Step-based Royalty Payment Three [Member] | Council License Agreement [Member] | ANNOVERA [Member] | Minimum [Member] |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |
Net sales amount per step-based royalty |  |  |  | $ 150,000,000 |  |  |  |  |
Step-based Royalty Payment Two [Member] | Council License Agreement [Member] | ANNOVERA [Member] |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |
Royalty (percent) |  |  |  | 10.00% |  |  |  |  |
Step-based Royalty Payment Two [Member] | Council License Agreement [Member] | ANNOVERA [Member] | Minimum [Member] |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |
Net sales amount per step-based royalty |  |  |  |  |  | $ 50,000,000 |  |  |
Step-based Royalty Payment Two [Member] | Council License Agreement [Member] | ANNOVERA [Member] | Maximum [Member] |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |
Net sales amount per step-based royalty |  |  |  | $ 150,000,000 |  |  |  |  |

X
- Definition Annual net sale milestones in the Territory per license agreement. + References No definition available. + Details
Name: | txmd_AnnualNetSalesMilestones
Namespace Prefix: | txmd_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The reduction in royalty rate of initial rate six-months after the first arms-length commercial sale of a generic equivalent of the one-year vaginal contraceptive system that is launched by a third party in the U.S. + References No definition available. + Details
Name: | txmd_AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent
Namespace Prefix: | txmd_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The reduction in royalty rate of the initial rate during the six-month period beginning on the date of the first arms-length commercial sale of a generic equivalent of the one-year vaginal contraceptive system that is launched by a third party in the U.S. + References No definition available. + Details
Name: | txmd_AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent
Namespace Prefix: | txmd_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of cash due as an upfront fee per signed agreement. + References No definition available. + Details
Name: | txmd_CashUpfrontPaymentDue
Namespace Prefix: | txmd_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition THe amount of intangibles written off. + References No definition available. + Details
Name: | txmd_IntangibleWrittenOfff
Namespace Prefix: | txmd_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of milestone payments payable after release of first commercial batch. + References No definition available. + Details
Name: | txmd_MilestonePaymentsAfterReleaseOfFirstCommercialBatch
Namespace Prefix: | txmd_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The amount of milestone payments payable upon FDA approval. + References No definition available. + Details
Name: | txmd_MilestonePaymentsUponFDAApproval
Namespace Prefix: | txmd_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The net sales amount as defined in license agreement for step-based royalty payments. + References No definition available. + Details
Name: | txmd_NetSalesAmountPerStepbasedRoyalty
Namespace Prefix: | txmd_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Number of issued patents. + References No definition available. + Details
Name: | txmd_NumberOfIssuedPatents
Namespace Prefix: | txmd_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition The cash inflow from the additional capital contribution to the entity. + References No definition available. + Details
Name: | txmd_ProceedsFromIssuanceOfCommonStock1
Namespace Prefix: | txmd_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of regulatory milestone payments based on regulatory approvals for each of BIJUVA and IMVEXXY in certain specified markets. + References No definition available. + Details
Name: | txmd_RegulatoryMilestonePaymentDue
Namespace Prefix: | txmd_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The percent of the net sales to be paid as royalty per license agreement. + References No definition available. + Details
Name: | txmd_RoyaltyPercent
Namespace Prefix: | txmd_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount of sales milestone payments to be paid in escalating tranches based on Theramex first attaining certain aggregate annual net sales milestones in the Territory. + References No definition available. + Details
Name: | txmd_SalesMilestonePayments
Namespace Prefix: | txmd_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a)(2) -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274 + Details
Name: | us-gaap_AmortizationOfIntangibleAssets
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + References No definition available. + Details
Name: | us-gaap_FiniteLivedIntangibleAssetUsefulLife
Namespace Prefix: | us-gaap_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_FiniteLivedIntangibleAssetsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (a)(1) -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275 + Details
Name: | us-gaap_FinitelivedIntangibleAssetsAcquired1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction. + References No definition available. + Details
Name: | us-gaap_SaleOfStockPricePerShare
Namespace Prefix: | us-gaap_
Data Type: | num:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of new stock issued during the period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details
Name: | us-gaap_StockIssuedDuringPeriodSharesNewIssues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_Patents5Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_Patents3Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_Patents1Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_Patents6Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_Patents4Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_Patents7Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_Patents2Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_Patents8Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_Patents11Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_Patents9Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_Patents10Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_Patents16Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsidiarySaleOfStockAxis=txmd_SubscriptionAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=txmd_KnightTherapeuticsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=txmd_CouncilLicenseAgreement1Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=txmd_AnnoveraMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | txmd_RoyaltyTierAxis=txmd_StepBasedRoyaltyPaymentOneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | txmd_RoyaltyTierAxis=txmd_StepBasedRoyaltyPaymentThreeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | txmd_RoyaltyTierAxis=txmd_StepBasedRoyaltyPaymentTwoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |